文献速递瓣膜外科

非agenarians经股动脉与经心尖TAVR结局分层分析

Transcatheter Aortic Valve Replacement Outcomes in Nonagenarians Stratified by Transfemoral and Transapical Approach.
PubMed 文献 · Ann Thorac Surg · 2017-04-24

基于2011-2013年Medicare数据库接受TAVR的18283例患者,19.3%为90岁及以上。90岁及以上患者30天和1年死亡率略高于年轻患者(8.4% vs 5.9%;25.4% vs 21.5%),但75%存活至1年;在该人群中经心尖入路较经股动脉入路结局更差。

要点

  • 90岁及以上患者TAVR后30天死亡率8.4%,1年死亡率25.4%,75%存活至1年。
  • 经心尖TAVR是非agenarians 30天死亡(OR 1.94)和再入院(OR 1.46)的独立预测因素。
  • 非agenarians经股动脉TAVR较经心尖入路30天和1年死亡率更低,出院回家比例更高。

核心结论

  • 非agenarians TAVR后30天和1年死亡率略差于年轻患者,但75%存活至1年,长期生存仍令人鼓舞。
  • 在非agenarians中,经心尖TAVR与更差结局相关。

研究设计与样本

  • 回顾性队列研究,纳入2011年11月至2013年接受TAVR的65岁及以上患者,共18283例,其中19.3%为90岁及以上。

主要发现

  • 90岁及以上患者30天死亡率为8.4%,低于90岁患者为5.9%(p=0.0001);1年死亡率分别为25.4%和21.5%(p=0.0001),OR 1.47(95%CI 1.28-1.70,p=0.0001)。
  • 90岁及以上患者起搏器植入率更高(11.1% vs 8.3%,p=0.0001)。
  • 在非agenarians中,经股动脉TAVR较经心尖入路30天死亡率更低(7.2% vs 13.6%,p=0.0001),1年死亡率更低(23.8% vs 31.6%,p=0.0001),出院回家比例更高(54.4% vs 34.1%,p=0.0001),30天再入院率更低(23.8% vs 31.8%,p=0.0001)。
  • 校正患者特征后,经心尖TAVR是30天死亡率(OR 1.94,95%CI 1.48-2.56,p=0.0001)和再入院(OR 1.46,95%CI 1.19-1.80,p=0.0003)的独立预测因素。

临床怎么用

  • 对非agenarians行TAVR时,优先考虑经股动脉入路以降低死亡和再入院风险。
  • 非agenarians TAVR后需关注起搏器植入风险。

局限性

  • 研究基于Medicare数据库,可能不涵盖所有TAVR患者。
  • 回顾性设计,存在选择偏倚可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Survival and other outcomes of nonagenarians undergoing transcatheter aortic valve replacement (TAVR) in the Medicare population are unclear. METHODS: Patients aged 65 years and older who underwent TAVR from November 2011 through 2013 were considered for inclusion. RESULTS: The study consisted of 18,283 patients and 19.3% were aged 90 years or older. Compared with patients younger than 90 years, patients 90 years or older were less likely to have a number of comorbidities, including previous myocardial infarction (17.5% versus 21.8%), previous coronary artery bypass grafting (20.0% versus 35.0%), and chronic obstructive pulmonary disease (25.4% versus 39.0%) among others. The 30-day and 1-year mortality rates were 8.4% versus 5.9% (p = 0.0001) and 25.4% versus 21.5% (p = 0.0001) in the older and younger groups, respectively (odds ratio [OR] 1.47, 95% confidence interval [CI]: 1.28 to 1.70, p = 0.0001). Patients 90 years and older were more likely to undergo pacemaker insertion (11.1% versus 8.3%, p = 0.0001). Among nonagenarians, compared with the transapical group, patients undergoing transfemoral TAVR had lower 30-day (7.2% versus 13.6%, p = 0.0001) and 1-year (23.8% versus 31.6%, p = 0.0001) mortality rates, were more likely to be discharged home (54.4% versus 34.1%, p = 0.0001), and had lower 30-day readmission rates (23.8% versus 31.8%, p = 0.0001). After adjustment for patient characteristics, transapical TAVR was an independent predictor of 30-day mortality rate (OR 1.94, 95% CI: 1.48 to 2.56, p = 0.0001) and readmission (OR 1.46, 95% CI: 1.19 to 1.80, p = 0.0003). CONCLUSIONS: In patients undergoing TAVR, although 30-day and 1-year mortality rates were slightly worse for nonagenarians than their younger counterparts, long-term survival was still encouraging, with 75% of nonagenarians living to 1 year. Transapical TAVR was associated with worse outcomes in nonagenarians.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. McNeely C, Zajarias A, Robbs R, et al. Transcatheter Aortic Valve Replacement Outcomes in Nonagenarians Stratified by Transfemoral and Transapical Approach. Ann Thorac Surg. 2017. PMID: 28450135. doi:10.1016/j.athoracsur.2017.02.056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。